Peregrine Pharmaceuticals Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial

Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments

Peregrine Pharmaceuticals Announces Significant Progress in Advancing Its Cotara Program Into a Pivotal Phase III Trial

Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012

Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ

New Data Support Ability of PS-Targeting Antibodies to Specifically Target Tumors and Stimulate Cancer-Fighting Immune Responses

Peregrine Pharmaceuticals Provides Update on Corporate Activities

Peregrine Pharmaceuticals Announces New Location of Annual Meeting of Stockholders

Peregrine to Participate in Credit Suisse 2012 Small & Mid Cap Conference on September 21, 2012